Skip to main content
NCBI home page
Journal of Clinical Pathology logoLink to Journal of Clinical Pathology
. 1992 Jun;45(6):461–464. doi: 10.1136/jcp.45.6.461

Pathogenesis of idiopathic myelofibrosis: role of growth factors.

J T Reilly 1
PMCID: PMC495214  PMID: 1624590

Full text

PDF
461

Images in this article

462Image
on p.462
463Image
on p.463
463Image
on p.463

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Apaja-Sarkkinen M., Autio-Harmainen H., Alavaikko M., Risteli J., Risteli L. Immunohistochemical study of basement membrane proteins and type III procollagen in myelofibrosis. Br J Haematol. 1986 Jul;63(3):571–580. doi: 10.1111/j.1365-2141.1986.tb07535.x. [DOI] [PubMed] [Google Scholar]
  2. Baglin T. P., Price S. M., Boughton B. J. A reversible defect of platelet PDGF content in myeloproliferative disorders. Br J Haematol. 1988 Aug;69(4):483–486. doi: 10.1111/j.1365-2141.1988.tb02403.x. [DOI] [PubMed] [Google Scholar]
  3. Barosi G., Costa A., Liberato L. N., Polino G., Spriano P., Magrini U. Serum procollagen-III-peptide level correlates with disease activity in myelofibrosis with myeloid metaplasia. Br J Haematol. 1989 May;72(1):16–20. doi: 10.1111/j.1365-2141.1989.tb07644.x. [DOI] [PubMed] [Google Scholar]
  4. Buschle M., Janssen J. W., Drexler H., Lyons J., Anger B., Bartram C. R. Evidence for pluripotent stem cell origin of idiopathic myelofibrosis: clonal analysis of a case characterized by a N-ras gene mutation. Leukemia. 1988 Oct;2(10):658–660. [PubMed] [Google Scholar]
  5. Caenazzo A., Pietrogrande F., Polato G., Piva E., Masiero M., Sgarabotto D., Girolami A. Changes in the mitogenic activity of platelet-derived growth factor(s) in patients with myeloproliferative disease. Acta Haematol. 1989;81(3):131–135. doi: 10.1159/000205544. [DOI] [PubMed] [Google Scholar]
  6. Carroll A., Civin C., Schneider N., Dahl G., Pappo A., Bowman P., Emami A., Gross S., Alvarado C., Phillips C. The t(1;22) (p13;q13) is nonrandom and restricted to infants with acute megakaryoblastic leukemia: a Pediatric Oncology Group Study. Blood. 1991 Aug 1;78(3):748–752. [PubMed] [Google Scholar]
  7. Castro-Malaspina H., Gay R. E., Jhanwar S. C., Hamilton J. A., Chiarieri D. R., Meyers P. A., Gay S., Moore M. A. Characteristics of bone marrow fibroblast colony-forming cells (CFU-F) and their progeny in patients with myeloproliferative disorders. Blood. 1982 May;59(5):1046–1054. [PubMed] [Google Scholar]
  8. Castro-Malaspina H., Rabellino E. M., Yen A., Nachman R. L., Moore M. A. Human megakaryocyte stimulation of proliferation of bone marrow fibroblasts. Blood. 1981 Apr;57(4):781–787. [PubMed] [Google Scholar]
  9. Charron D., Robert L., Couty M. C., Binet J. L. Biochemical and histological analysis of bone marrow collagen in myelofibrosis. Br J Haematol. 1979 Feb;41(2):151–161. doi: 10.1111/j.1365-2141.1979.tb05843.x. [DOI] [PubMed] [Google Scholar]
  10. Dolan G., Forrest P. L., Eastham J. M., Reilly J. T. Reduced platelet PDGF levels in idiopathic myelofibrosis. Br J Haematol. 1991 Aug;78(4):586–588. doi: 10.1111/j.1365-2141.1991.tb04503.x. [DOI] [PubMed] [Google Scholar]
  11. Drouet L., Praloran V., Cywiner-Golenzer C., Trehen C., Flandrin G., Caen J. P. Déficit congénital en alpha granules plaquettaires et fibrose réticulinique médullaire, Hypothèses physiopathogènique. Nouv Rev Fr Hematol. 1981;23(2):95–100. [PubMed] [Google Scholar]
  12. Fava R. A., Casey T. T., Wilcox J., Pelton R. W., Moses H. L., Nanney L. B. Synthesis of transforming growth factor-beta 1 by megakaryocytes and its localization to megakaryocyte and platelet alpha-granules. Blood. 1990 Nov 15;76(10):1946–1955. [PubMed] [Google Scholar]
  13. Gay S., Gay R. E., Prchal J. T. Immunohistological studies of bone marrow collagen. Prog Clin Biol Res. 1984;154:291–306. [PubMed] [Google Scholar]
  14. Gersuk G. M., Carmel R., Pattengale P. K. Platelet-derived growth factor concentrations in platelet-poor plasma and urine from patients with myeloproliferative disorders. Blood. 1989 Nov 15;74(7):2330–2334. [PubMed] [Google Scholar]
  15. Gilbert H. S., Praloran V., Stanley E. R. Increased circulating CSF-1 (M-CSF) in myeloproliferative disease: association with myeloid metaplasia and peripheral bone marrow extension. Blood. 1989 Sep;74(4):1231–1234. [PubMed] [Google Scholar]
  16. Gilliland D. G., Blanchard K. L., Levy J., Perrin S., Bunn H. F. Clonality in myeloproliferative disorders: analysis by means of the polymerase chain reaction. Proc Natl Acad Sci U S A. 1991 Aug 1;88(15):6848–6852. doi: 10.1073/pnas.88.15.6848. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Gimsing P., Bjerrum O. W., Brandt E., Ellegaard J., Evensen S. A., Hansen M. M., Hedenus M., Hippe E., Keldsen N., Palva I. Refractory myelomatosis treated with mitoxantrone in combination with vincristine and prednisone (NOP-regimen): a phase II study. The Nordic Myeloma Study Group (NMSG) Br J Haematol. 1991 Jan;77(1):73–79. doi: 10.1111/j.1365-2141.1991.tb07951.x. [DOI] [PubMed] [Google Scholar]
  18. Gimsing P., Bjerrum O. W., Brandt E., Ellegaard J., Evensen S. A., Hansen M. M., Hedenus M., Hippe E., Keldsen N., Palva I. Refractory myelomatosis treated with mitoxantrone in combination with vincristine and prednisone (NOP-regimen): a phase II study. The Nordic Myeloma Study Group (NMSG) Br J Haematol. 1991 Jan;77(1):73–79. doi: 10.1111/j.1365-2141.1991.tb07951.x. [DOI] [PubMed] [Google Scholar]
  19. Greenberg B. R., Woo L., Veomett I. C., Payne C. M., Ahmann F. R. Cytogenetics of bone marrow fibroblastic cells in idiopathic chronic myelofibrosis. Br J Haematol. 1987 Aug;66(4):487–490. doi: 10.1111/j.1365-2141.1987.tb01332.x. [DOI] [PubMed] [Google Scholar]
  20. Hasselbalch H., Junker P., Lisse I., Bentsen K. D., Risteli L., Risteli J. Serum markers for type IV collagen and type III procollagen in the myelofibrosis-osteomyelosclerosis syndrome and other chronic myeloproliferative disorders. Am J Hematol. 1986 Oct;23(2):101–111. doi: 10.1002/ajh.2830230204. [DOI] [PubMed] [Google Scholar]
  21. Heldin C. H., Westermark B., Wasteson A. Platelet-derived growth factor: purification and partial characterization. Proc Natl Acad Sci U S A. 1979 Aug;76(8):3722–3726. doi: 10.1073/pnas.76.8.3722. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Hibbin J. A., Njoku O. S., Matutes E., Lewis S. M., Goldman J. M. Myeloid progenitor cells in the circulation of patients with myelofibrosis and other myeloproliferative disorders. Br J Haematol. 1984 Jul;57(3):495–503. doi: 10.1111/j.1365-2141.1984.tb02924.x. [DOI] [PubMed] [Google Scholar]
  23. Jacobson R. J., Salo A., Fialkow P. J. Agnogenic myeloid metaplasia: a clonal proliferation of hematopoietic stem cells with secondary myelofibrosis. Blood. 1978 Feb;51(2):189–194. [PubMed] [Google Scholar]
  24. Janssen J. W., Steenvoorden A. C., Lyons J., Anger B., Böhlke J. U., Bos J. L., Seliger H., Bartram C. R. RAS gene mutations in acute and chronic myelocytic leukemias, chronic myeloproliferative disorders, and myelodysplastic syndromes. Proc Natl Acad Sci U S A. 1987 Dec;84(24):9228–9232. doi: 10.1073/pnas.84.24.9228. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Katoh O., Kimura A., Itoh T., Kuramoto A. Platelet derived growth factor messenger RNA is increased in bone marrow megakaryocytes in patients with myeloproliferative disorders. Am J Hematol. 1990 Nov;35(3):145–150. doi: 10.1002/ajh.2830350302. [DOI] [PubMed] [Google Scholar]
  26. Katoh O., Kimura A., Kuramoto A. Platelet-derived growth factor is decreased in patients with myeloproliferative disorders. Am J Hematol. 1988 Apr;27(4):276–280. doi: 10.1002/ajh.2830270409. [DOI] [PubMed] [Google Scholar]
  27. Kimura A., Katoh O., Hyodo H., Kuramoto A. Transforming growth factor-beta regulates growth as well as collagen and fibronectin synthesis of human marrow fibroblasts. Br J Haematol. 1989 Aug;72(4):486–491. doi: 10.1111/j.1365-2141.1989.tb04310.x. [DOI] [PubMed] [Google Scholar]
  28. Kimura A., Katoh O., Hyodo H., Kusumi S., Kuramoto A. Autocrine and/or paracrine mechanism operate during the growth of human bone marrow fibroblasts. Br J Haematol. 1991 Aug;78(4):469–473. doi: 10.1111/j.1365-2141.1991.tb04474.x. [DOI] [PubMed] [Google Scholar]
  29. Kreipe H., Jaquet K., Felgner J., Radzun H. J., Parwaresch M. R. Clonal granulocytes and bone marrow cells in the cellular phase of agnogenic myeloid metaplasia. Blood. 1991 Oct 1;78(7):1814–1817. [PubMed] [Google Scholar]
  30. Marcus R. E., Hibbin J. A., Matutes E., Whittle N., Waterfield M. D., Goldman J. M. Megakaryoblastic transformation of myelofibrosis with expression of the c-sis oncogene. Scand J Haematol. 1986 Feb;36(2):186–193. doi: 10.1111/j.1600-0609.1986.tb00826.x. [DOI] [PubMed] [Google Scholar]
  31. Martyré M. C., Magdelenat H., Bryckaert M. C., Laine-Bidron C., Calvo F. Increased intraplatelet levels of platelet-derived growth factor and transforming growth factor-beta in patients with myelofibrosis with myeloid metaplasia. Br J Haematol. 1991 Jan;77(1):80–86. doi: 10.1111/j.1365-2141.1991.tb07952.x. [DOI] [PubMed] [Google Scholar]
  32. Mertens F., Johansson B., Heim S., Kristoffersson U., Mitelman F. Karyotypic patterns in chronic myeloproliferative disorders: report on 74 cases and review of the literature. Leukemia. 1991 Mar;5(3):214–220. [PubMed] [Google Scholar]
  33. Overall C. M., Wrana J. L., Sodek J. Independent regulation of collagenase, 72-kDa progelatinase, and metalloendoproteinase inhibitor expression in human fibroblasts by transforming growth factor-beta. J Biol Chem. 1989 Jan 25;264(3):1860–1869. [PubMed] [Google Scholar]
  34. Pagliuca A., Layton D. M., Manoharan A., Gordon S., Green P. J., Mufti G. J. Myelofibrosis in primary myelodysplastic syndromes: a clinico-morphological study of 10 cases. Br J Haematol. 1989 Apr;71(4):499–504. doi: 10.1111/j.1365-2141.1989.tb06309.x. [DOI] [PubMed] [Google Scholar]
  35. Reilly J. T., Dolan G. Proposed classification for the myelodysplasia/myelofibrosis syndromes. Br J Haematol. 1991 Dec;79(4):653–653. doi: 10.1111/j.1365-2141.1991.tb08099.x. [DOI] [PubMed] [Google Scholar]
  36. Reilly J. T., Nash J. R., Mackie M. J., McVerry B. A. Endothelial cell proliferation in myelofibrosis. Br J Haematol. 1985 Aug;60(4):625–630. doi: 10.1111/j.1365-2141.1985.tb07465.x. [DOI] [PubMed] [Google Scholar]
  37. Reilly J. T., Nash J. R., Mackie M. J., McVerry B. A. Immuno-enzymatic detection of fibronectin in normal and pathological haematopoietic tissue. Br J Haematol. 1985 Mar;59(3):497–504. doi: 10.1111/j.1365-2141.1985.tb07336.x. [DOI] [PubMed] [Google Scholar]
  38. Reilly J. T., Nash J. R. Vitronectin (serum spreading factor): its localisation in normal and fibrotic tissue. J Clin Pathol. 1988 Dec;41(12):1269–1272. doi: 10.1136/jcp.41.12.1269. [DOI] [PMC free article] [PubMed] [Google Scholar]
  39. Roberts A. B., Sporn M. B., Assoian R. K., Smith J. M., Roche N. S., Wakefield L. M., Heine U. I., Liotta L. A., Falanga V., Kehrl J. H. Transforming growth factor type beta: rapid induction of fibrosis and angiogenesis in vivo and stimulation of collagen formation in vitro. Proc Natl Acad Sci U S A. 1986 Jun;83(12):4167–4171. doi: 10.1073/pnas.83.12.4167. [DOI] [PMC free article] [PubMed] [Google Scholar]
  40. Romano M., Viero P., Cortellazzo S., Barbui T., Donati M. B., Poggi A. Platelet-derived mitogenic activity and bone marrow fibrosis in myeloproliferative disorders. Haemostasis. 1990;20(3):162–168. doi: 10.1159/000216123. [DOI] [PubMed] [Google Scholar]
  41. Rondeau E., Solal-Celigny P., Dhermy D., Vroclans M., Brousse N., Bernard J. F., Boivin P. Immune disorders in agnogenic myeloid metaplasia: relations to myelofibrosis. Br J Haematol. 1983 Mar;53(3):467–475. doi: 10.1111/j.1365-2141.1983.tb02048.x. [DOI] [PubMed] [Google Scholar]
  42. Rozman C., Giralt M., Feliu E., Rubio D., Cortés M. T. Life expectancy of patients with chronic nonleukemic myeloproliferative disorders. Cancer. 1991 May 15;67(10):2658–2663. doi: 10.1002/1097-0142(19910515)67:10<2658::aid-cncr2820671042>3.0.co;2-c. [DOI] [PubMed] [Google Scholar]
  43. Rueda F., Piñol G., Marti F., Pujol-Moix N. Abnormal levels of platelet-specific proteins and mitogenic activity in myeloproliferative disease. Acta Haematol. 1991;85(1):12–15. doi: 10.1159/000204844. [DOI] [PubMed] [Google Scholar]
  44. Sacchi S., Curci G., Piccinini L., Messerotti A., Cucci F., Bursi R., Zaniol P., Torelli U. Platelet alpha-granule release in chronic myeloproliferative disorders with thrombocytosis. Scand J Clin Lab Invest. 1986 Apr;46(2):163–166. doi: 10.3109/00365518609083653. [DOI] [PubMed] [Google Scholar]
  45. Sunami S., Fuse A., Simizu B., Eguchi M., Hayashi Y., Sugita K., Nakazawa S., Okimoto Y., Sato T., Nakajima H. The c-sis gene expression in cells from a patient with acute megakaryoblastic leukemia and Down's syndrome. Blood. 1987 Aug;70(2):368–371. [PubMed] [Google Scholar]
  46. Terui T., Niitsu Y., Mahara K., Fujisaki Y., Urushizaki Y., Mogi Y., Kohgo Y., Watanabe N., Ogura M., Saito H. The production of transforming growth factor-beta in acute megakaryoblastic leukemia and its possible implications in myelofibrosis. Blood. 1990 Apr 1;75(7):1540–1548. [PubMed] [Google Scholar]
  47. Varga J., Rosenbloom J., Jimenez S. A. Transforming growth factor beta (TGF beta) causes a persistent increase in steady-state amounts of type I and type III collagen and fibronectin mRNAs in normal human dermal fibroblasts. Biochem J. 1987 Nov 1;247(3):597–604. doi: 10.1042/bj2470597. [DOI] [PMC free article] [PubMed] [Google Scholar]
  48. den Ottolander G. J., te Velde J., Brederoo P., Geraedts J. P., Slee P. H., Willemze R., Zwaan F. E., Haak H. L., Muller H. P., Bieger R. Megakaryoblastic leukaemia (acute myelofibrosis): a report of three cases. Br J Haematol. 1979 May;42(1):9–20. doi: 10.1111/j.1365-2141.1979.tb03693.x. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Clinical Pathology are provided here courtesy of BMJ Publishing Group

RESOURCES